The Stability Program is being conducted in collaboration with HYTN’s GMP-licensed laboratory partner. Upon successful completion, HYTN expects to provide an initial six-month stability statement for ...
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing the tuspetinib (TUS)-based triple drug frontline therapy to treat ...
ESMA proposes new guidelines requiring crypto service providers to ensure staff meet qualification standards and undergo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback